



52 y/o WF
with T2DM
and HTN,
last A1C 6.2


- CTL user in monovision
- OD
 - 20/20 -1
 - IOP 17
 - 1+ NS
- OS
 - 20/50 -> 20/25 OS
 - IOP 19
 - Prior year 20/20-2
 - 2-3+NS with cortical changes
- Metformin 500 mg BID
- Losartan 25mg QD
- Semaglutide 1 mg QW
- Brimonidine/timolol BID OU
- Questions to consider
 - Changes in current medications
 - Discussion about cataract surgery
 - Concern with GLP1
















Macula Thickness : Macular Cube 512x128

OD ● ○ OS




Fovea: 270, 65


Overlay: ILM - RPE Transparency: 50 %




ILM - RPE




ILM



RPE






	Central Subfield Thickness (μm)	Cube Volume (mm ³)	Cube Average Thickness (μm)
ILM - RPE	269	10.0	278



69

Macula Thickness : Macular Cube 512x128



OD ○ ● OS




Fovea: 263, 67

Overlay: ILM - RPE Transparency: 50 %


High-definition mode




ILM - RPE




ILM



RPE



	Central Subfield Thickness (μm)	Cube Volume (mm ³)	Cube Average Thickness (μm)
ILM - RPE	300	11.0	306




64

270

256



53yo WF
Vision
20/20



53yo WF
Vision
CF@6in


61 y/o AAF with
T2DM, smokes
"occasionally"
last A1C 7.5

- OD
 - 20/50+1
 - IOP 10
 - 2+ NS
- OS
 - 20/20 -1
 - IOP 10
 - 2+ NS






- Pioglitazone 30mg QD
- Dapagliflozin/Metformin 5/1000 tablet BID
- Treieba 22units SQ QD
- Rosuvastatin 20mg QD
- Omeprazole 40mg QD
- Restasis OU BID
- Questions to consider
 - Changes in current medications
 - Concern with GLP1

Macula Thickness : Macular Cube 512x128

OD ● ○ OS




Overlay: ILM - RPE Transparency: 50 %








	Central Subfield Thickness (μm)	Cube Volume (mm^3)	Cube Average Thickness (μm)
ILM - RPE	329	12.7	354

Macula Thickness : Macular Cube 512x128

OD ○ ● OS




Overlay: ILM - RPE Transparency: 50 %








	Central Subfield Thickness (μm)	Cube Volume (mm^3)	Cube Average Thickness (μm)
ILM - RPE	221	10.1	280

Macula Thickness : Macular Cube 512x128

OD ● ○ OS




Overlay: ILM - RPE Transparency: 50 %








⚠	Central Subfield Thickness (μm)	Cube Volume (mm^3)	Cube Average Thickness (μm)
ILM - RPE	258	10.2	282

Macula Thickness : Macular Cube 512x128

OD ○ ● OS



Overlay: ILM - RPE Transparency: 50 %



⚠	Central Subfield Thickness (μm)	Cube Volume (mm^3)	Cube Average Thickness (μm)
ILM - RPE	282	11.0	305


Eylea 2mg OD x 10 last dose July 7, 2021

Started Eylea 2mg OS


February 21, 2022

Eylea HD OD x 7 last dose on March 2025 and Eylea HD OS x 2 last dose November 2024

Macula Thickness : Macular Cube 512x128 OD ● ○ OS



Macula Thickness : Macular Cube 512x128 OD ○ ● OS




72 y/o HM with
T2DM, CKD, OSA
on CPAP, HLD,
and last A1C 6.1
(down from 8.9)

- Inferior field loss OS x
1-2 weeks
- OD
 - 20/20
 - IOP 17
 - 2+ NS
- OS
 - 20/60
 - IOP 11
 - 2+ NS

- Empagliflozin 10mg QD
- Sitagliptin/Metformin
50/1000 tablet BID
- Atorvastatin 80mg QD
- Semaglutide 1mg QW
 - Started 8 months ago
- Questions to consider
 - Changes in current
medications
 - Concern with GLP1






Macula Thickness : Macular Cube 512x128

OD OS



Overlay: ILM - RPE Transparency: 50 %


High-definition mode



	Central Subfield Thickness (μm)	Cube Volume (mm^3)	Cube Average Thickness (μm)
ILM - RPE	323	10.8	299






Macula Thickness : Macular Cube 512x128

OD OS




Overlay: ILM - RPE Transparency: 50 %

High-definition mode





	Central Subfield Thickness (μm)	Cube Volume (mm^3)	Cube Average Thickness (μm)
ILM - RPE	509	12.1	336




Macula Thickness : Macular Cube 512x128

OD OS






ILM-RPE Thickness (μm)




Fovea: 258, 63

Overlay: ILM - RPE Transparency: 50 %


High-definition mode




ILM - RPE



ILM



RPE



	Central Subfield Thickness (μm)	Cube Volume (mm^3)	Cube Average Thickness (μm)
ILM - RPE	318	10.8	299



Comments

Doctor's Signature


SW Ver: 11.5.2.54532
Copyright 2020
Carl Zeiss Meditec, Inc
All Rights Reserved
Page 1 of 1

Macula Thickness : Macular Cube 512x128

OD OS






ILM-RPE Thickness (μm)




Fovea: 255, 64

Overlay: ILM - RPE Transparency: 50 %


High-definition mode




ILM - RPE



ILM



RPE



	Central Subfield Thickness (μm)	Cube Volume (mm^3)	Cube Average Thickness (μm)
ILM - RPE	275	9.4	261

Comments

Doctor's Signature

SW Ver: 11.5.2.54532
Copyright 2020
Carl Zeiss Meditec, Inc
All Rights Reserved
Page 1 of 1